GlassScriptPhysician profile
Alex Speer
NPI 1972131563
$405.10
in general payments reported to CMS, 2019-2025
10 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $69.92 · 2024: $235 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $142.37 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $60.68 | 2024 | |
| Globus Medical, INC. | $43.77 | 2025 | Senza |
| Averitas Pharma INC. | $37.42 | 2023 | Qutenza |
| Nevro Corp. | $33.52 | 2024 | Senza |
| Boston Scientific Corporation | $21.87 | 2025 | General - Pain Management |
| Saluda Medical Americas, INC. | $20.91 | 2025 | Evoke |
| Amgen INC. | $16.69 | 2024 | Krystexxa |
| Smith+Nephew, INC. | $14.08 | 2024 | Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $13.79 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Speer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.